QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=7116CFF2C305E39B6A5ADB16A592939D;jsessionid=AFF1F23CF9A361EB3339FDB3B904FD7E;jsessionid=66BB629E20E251924C3E2AE67272E81A;jsessionid=43F3F7E7B6F5BFC83D14ABAB94F582CA;jsessionid=4F01AF154F572AF0904ECAFCEFB4B22D (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=7116CFF2C305E39B6A5ADB16A592939D;jsessionid=AFF1F23CF9A361EB3339FDB3B904FD7E;jsessionid=66BB629E20E251924C3E2AE67272E81A;jsessionid=43F3F7E7B6F5BFC83D14ABAB94F582CA;jsessionid=4F01AF154F572AF0904ECAFCEFB4B22D